Higher Concentrations of Parathyroid Hormone (PTH) are Associated with Reduced Gait Velocity in Adults: A Systematic Review.

What It Covers

Researchers studied Parathyroid Hormone (PTH 1-84) in this systematic review publication.

Gait velocity is a predictor of adverse outcomes.

This systematic review aimed to assess the observational evidence studying the association of PTH concentrations with gait velocity in adults.

Who the Included Studies Covered

The researchers searched PubMed, Embase (Ovid interface) and Cochrane (CENTRAL) for published studies evaluating circulating PTH in human adults aged >20 years, without date or language restriction.

The researchers excluded studies with patients on dialysis and if PTH was measured following any intervention having a potential effect on its concentrations.

How the Review Was Done

Primary outcome was gait velocity, defined as the time needed to walk a predetermined distance or distance walked during a fixed period at usual pace or fast pace.

Two independent researchers conducted data extraction and evaluated the risk of bias.

A third reviewer resolved disagreements.

Risk of bias assessment was done using the National Heart, Lung and Blood Institute quality assessment tool.

What Was Measured

Topics PubMed links to this paper include Gait, Osteoporosis, Parathyroid Hormone, Sarcopenia and Walking Speed.

The authors tagged it with the keywords falls, fractures, gait velocity and osteosarcopenia.

What This Means in Plain Language

This is a systematic review of Parathyroid Hormone (PTH 1-84).

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (Archives of gerontology and geriatrics), a journal based in Netherlands.

More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.